# Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

> **NCT01374516** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 20869 (actual)

## Conditions studied

- Dengue Fever
- Dengue Hemorrhagic Fever
- Dengue

## Interventions

- **BIOLOGICAL:** Live, attenuated, dengue serotype 1, 2, 3, 4 virus
- **BIOLOGICAL:** Placebo: (NaCl) 0.9% solution

## Key facts

- **NCT ID:** NCT01374516
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-08
- **Primary completion:** 2014-11
- **Final completion:** 2018-03-05
- **Target enrollment:** 20869 (ACTUAL)
- **Last updated:** 2022-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01374516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01374516, "Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01374516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*